LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has postponed the release of its fourth-quarter and year-end 2008 financial results and its year-end conference call previously scheduled for Thursday, March 12, 2009. Synta is postponing the earnings release and call because additional time is required to allow Synta to complete its review of certain additional disclosures and financial implications relating to the Company’s decision, previously announced on February 26, 2009, to suspend the clinical development of elesclomol, including the Phase 3 clinical trial of elesclomol in metastatic melanoma (SYMMETRY(SM)). Synta also expects that it will need to file for an extension to file its Annual Report on Form 10-K for the year ended December 31, 2008, but expects to file the Form 10-K as soon as it is able and within the 15-day extension period allowed pursuant to SEC rules, which will end on March 31, 2009.
